Literature DB >> 11413249

The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase.

L De Petrocellis1, S Harrison, T Bisogno, M Tognetto, I Brandi, G D Smith, C Creminon, J B Davis, P Geppetti, V Di Marzo.   

Abstract

The endogenous cannabinoid receptor ligand, anandamide (AEA), is a full agonist of the vanilloid receptor type 1 (VR1) for capsaicin. Here, we demonstrate that the potency and efficacy of AEA at VR1 receptors can be significantly increased by the concomitant activation of protein kinase A (PKA). In human embryonic kidney (HEK) cells over-expressing human VR1, AEA induces a rise in cytosolic Ca(2+) concentration that is mediated by this receptor. The EC(50) for this effect was decreased five-fold in the presence of forskolin (FRSK, 1-5 microM) or the cAMP analogue, 8-Br-cAMP (10-100 microM). The effects of 8-Br-cAMP and FRSK were blocked by a selective PKA inhibitor. The FRSK (10 nM) also potently enhanced the sensory neurone- and VR1-mediated constriction by AEA of isolated guinea-pig bronchi, and this effect was abolished by a PKA inhibitor. In rat dorsal root ganglia slices, AEA-induced release of substance P, an effect mediated by VR1 activation, was enhanced three-fold by FRSK (10 nM). Thus, the ability of AEA to stimulate sensory VR1, with subsequent neuropeptide release, appears to be regulated by the state of activation of PKA. This observation supports the hypothesis that endogenous AEA might stimulate VR1 under certain pathophysiological conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413249     DOI: 10.1046/j.1471-4159.2001.00406.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  63 in total

Review 1.  Cough. 5: The type 1 vanilloid receptor: a sensory receptor for cough.

Authors:  A H Morice; P Geppetti
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

Review 2.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

Review 3.  International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family.

Authors:  Long-Jun Wu; Tara-Beth Sweet; David E Clapham
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 4.  Structure-function analysis of TRPV channels.

Authors:  Barbara A Niemeyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04       Impact factor: 3.000

Review 5.  New insights into protease-activated receptor 4 signaling pathways in the pathogenesis of inflammation and neuropathic pain: a literature review.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Honggang Zheng; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015       Impact factor: 2.581

Review 6.  TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.

Authors:  António Avelino; Francisco Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-24       Impact factor: 3.000

7.  The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis.

Authors:  A Miranda; E Nordstrom; A Mannem; C Smith; B Banerjee; J N Sengupta
Journal:  Neuroscience       Date:  2007-08-23       Impact factor: 3.590

Review 8.  Anandamide and vanilloid TRPV1 receptors.

Authors:  Ruth A Ross
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

9.  Jejunal afferent nerve sensitivity in wild-type and TRPV1 knockout mice.

Authors:  Weifang Rong; Kirk Hillsley; John B Davis; Gareth Hicks; Wendy J Winchester; David Grundy
Journal:  J Physiol       Date:  2004-08-26       Impact factor: 5.182

10.  The endoplasmic reticulum of dorsal root ganglion neurons contains functional TRPV1 channels.

Authors:  Sonia Gallego-Sandín; Arancha Rodríguez-García; María Teresa Alonso; Javier García-Sancho
Journal:  J Biol Chem       Date:  2009-09-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.